Pro-Dex Jumps 15% as Next-Gen Handpiece Lifts Q4 Sales 17%
PDEX has more than doubled off its 52-week low of $23.47.
Summary
Pro-Dex shares surged 15% to $71.07 midday Friday after fiscal Q4 revenue rose 17% to $20.4 million, driven by resumed shipments of its biggest customer's next-generation orthopedic handpiece. The customer had held the product for most of the quarter, releasing it late in the period, which allowed Pro-Dex to restart production and shipments. Profit more than doubled to $2.9 million, or 87 cents a share, from $1.2 million, or 36 cents, a year earlier. This follows the 10-K filed yesterday showing full-year net income up 52% to $13.7 million and cash surging to $8.2 million. The stock's 88% year-to-date gain reflects strong execution and the handpiece ramp, but the late-quarter release timing raises questions about sustainability into fiscal 2027.
At the time of this announcement, PDEX was trading at $72.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231.3M. The 52-week trading range was $23.47 to $77.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.